- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05913544
Thérapie courte intégrative et neurocognitive pour les jeunes adultes présentant un trouble de la personnalité borderline (SINTYA)
Thérapie intégrative et neurocognitive courte pour les jeunes adultes atteints d'un trouble de la personnalité borderline : un modèle d'étude de la gestion de l'impulsivité
Borderline personality disorder (BPD) is a severe, high-suicidal psychiatric disorder associated with impulsive, endangering behaviors. Young patients between 16 and 25 years old do not respond to traditional psychotherapies, which are often long and not adapted to their neurocognitive alterations linked to early trauma. The study authors hypothesize the SINTYA therapy program (one group session and one individual session weekly for 10 weeks) would reduce the level of impulsivity and clinical symptomatology (severity of the BPD; emotional regulation difficulties; dissociative symptoms; aggressiveness; ruminations; the number of self-destructive behaviors and suicidal acts; impulsive behaviors; level of suicide risk and hopelessness; the number of psychiatric hospitalizations and emergency visits for psychiatric reasons; and finally improving psychosocial functioning).
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
-
Nîmes, France
- CHU de Nîmes
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Diagnosis of BPD according to DSM-5 criteria and BPQ-80 scale.
- High BPD severity level: ZAN-BPD (score ≥ 18/36).
- Understand, write and read French.
- Be able to understand the nature, purpose and methodology of the study and agree to cooperate during evaluations.
- Have signed the informed consent.
- For minor patients, have signed the parental consent by at least one holder of parental authority.
Exclusion Criteria:
- Refusal to participate.
- Existence of a neurological pathology or cerebral sequelae of organic origin which could affect neurocognitive performance.
- Intelligence quotient < 70.
- Lifetime diagnosis of schizoaffective disorder or schizophrenia (MINI-7).
- Previous or current participation in specific psychotherapy for BPD.
- Subject deprived of liberty (by judicial or administrative decision) and/or protected by law.
- Inclusion in another study including psychotherapy for the duration of the study.
- Inclusion in a drug RIPH1 study or in a REC study (European regulation of clinical trials) for the entire duration of the study.
- Subject in period of exclusion from another research protocol.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Aucune intervention: Contrôler
|
|
|
Expérimental: Groupe SINTYA
|
10-week psychotherapy program consisting of a weekly 1h30 hour group therapy session plus 1 hour individual therapy session |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Variation in explicit impulsivity between groups
Délai: Baseline
|
UPPS-S (Impulsive Behavior Scale Short version score) |
Baseline
|
|
Variation in explicit impulsivity between groups
Délai: Month 4
|
UPPS-S (Impulsive Behavior Scale Short version score) |
Month 4
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Variation in explicit impulsivity between groups
Délai: Month 7
|
UPPS-S (Impulsive Behavior Scale Short version score) |
Month 7
|
|
Variation in impulsiveness between groups
Délai: Baseline
|
Barratt Impulsiveness Scale (BIS-11) (score out of 120) |
Baseline
|
|
Variation in impulsiveness between groups
Délai: Month 4
|
Barratt Impulsiveness Scale (BIS-11) (score out of 120) |
Month 4
|
|
Variation in impulsiveness between groups
Délai: Month 7
|
Barratt Impulsiveness Scale (BIS-11) (score out of 120) |
Month 7
|
|
BPD severity level between groups
Délai: Baseline
|
Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD) (score out of 36) |
Baseline
|
|
BPD severity level between groups
Délai: Month 4
|
Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD) (score out of 36) |
Month 4
|
|
BPD severity level between groups
Délai: Month 7
|
Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD) (score out of 36) |
Month 7
|
|
Emotional regulation capacities between groups
Délai: Baseline
|
Difficulties in Emotion Regulation Scale (DERS-18) |
Baseline
|
|
Emotional regulation capacities between groups
Délai: Month 4
|
Difficulties in Emotion Regulation Scale (DERS-18) |
Month 4
|
|
Emotional regulation capacities between groups
Délai: Month 7
|
Difficulties in Emotion Regulation Scale (DERS-18) |
Month 7
|
|
Dissociative symptoms between groups
Délai: Baseline
|
Dissociative Experiences Scale (DES): a score of 25 or higher is predictive of dissociative disorder |
Baseline
|
|
Dissociative symptoms between groups
Délai: Month 4
|
Dissociative Experiences Scale (DES): a score of 25 or higher is predictive of dissociative disorder |
Month 4
|
|
Dissociative symptoms between groups
Délai: Month 7
|
Dissociative Experiences Scale (DES): a score of 25 or higher is predictive of dissociative disorder |
Month 7
|
|
Aggression between groups
Délai: Baseline
|
Aggression Questionnaire (AQ-12) |
Baseline
|
|
Aggression between groups
Délai: Month 4
|
Aggression Questionnaire (AQ-12) |
Month 4
|
|
Aggression between groups
Délai: Month 7
|
Aggression Questionnaire (AQ-12) |
Month 7
|
|
Ruminations between groups
Délai: Baseline
|
Rumination Reflection Questionnaire (RRQ) |
Baseline
|
|
Ruminations between groups
Délai: Month 4
|
Rumination Reflection Questionnaire (RRQ) |
Month 4
|
|
Ruminations between groups
Délai: Month 7
|
Rumination Reflection Questionnaire (RRQ) |
Month 7
|
|
Number of self-destructive behaviors between groups
Délai: Baseline
|
Number of self-destructive/self-mutilatory/parasuicidal acts reported by the patient in a clinical interview |
Baseline
|
|
Number of self-destructive behaviors between groups
Délai: Month 4
|
Number of self-destructive/self-mutilatory/parasuicidal acts reported by the patient in a clinical interview |
Month 4
|
|
Number of self-destructive behaviors between groups
Délai: Month 7
|
Number of self-destructive/self-mutilatory/parasuicidal acts reported by the patient in a clinical interview |
Month 7
|
|
Number of impulsive behaviors between groups
Délai: Baseline
|
Number of impulsive behaviors (food, motor vehicles, sexual, drug-related) |
Baseline
|
|
Number of impulsive behaviors between groups
Délai: Month 4
|
Number of impulsive behaviors (food, motor vehicles, sexual, drug-related) |
Month 4
|
|
Number of impulsive behaviors between groups
Délai: Month 7
|
Number of impulsive behaviors (food, motor vehicles, sexual, drug-related) |
Month 7
|
|
Level of suicide risk between groups
Délai: Baseline
|
Columbia-Suicide Severity Rating Scale (C-SSRS) |
Baseline
|
|
Level of suicide risk between groups
Délai: Month 4
|
Columbia-Suicide Severity Rating Scale (C-SSRS) |
Month 4
|
|
Level of suicide risk between groups
Délai: Month 7
|
Columbia-Suicide Severity Rating Scale (C-SSRS) |
Month 7
|
|
Number of psychiatric hospitalizations and emergency visits for psychiatric reasons between groups
Délai: 12 Months prior to inclusion
|
Information taken from patient medical file |
12 Months prior to inclusion
|
|
Number of psychiatric hospitalizations and emergency visits for psychiatric reasons between groups
Délai: Baseline
|
Information taken from patient medical file |
Baseline
|
|
Number of psychiatric hospitalizations and emergency visits for psychiatric reasons between groups
Délai: Month 4
|
Information taken from patient medical file |
Month 4
|
|
Number of psychiatric hospitalizations and emergency visits for psychiatric reasons between groups
Délai: Month 7
|
Information taken from patient medical file |
Month 7
|
|
Psychosocial functioning between groups
Délai: Baseline
|
Functional Assessment Staging Tool (FAST) |
Baseline
|
|
Psychosocial functioning between groups
Délai: Month 4
|
Functional Assessment Staging Tool (FAST) |
Month 4
|
|
Psychosocial functioning between groups
Délai: Month 7
|
Functional Assessment Staging Tool (FAST) |
Month 7
|
|
Implicit impulsivity between groups
Délai: Baseline
|
Continuous Performance Test (CPT) |
Baseline
|
|
Implicit impulsivity between groups
Délai: Month 4
|
Continuous Performance Test (CPT) |
Month 4
|
|
Implicit impulsivity between groups
Délai: Month 7
|
Continuous Performance Test (CPT) |
Month 7
|
|
Neurocognitive evaluation of implicit impulsivity between groups
Délai: Baseline
|
Emotional Stroop (SE) customized to the study |
Baseline
|
|
Neurocognitive evaluation of implicit impulsivity between groups
Délai: Month 4
|
Emotional Stroop (SE) customized to the study |
Month 4
|
|
Neurocognitive evaluation of implicit impulsivity between groups
Délai: Month 7
|
Emotional Stroop (SE) customized to the study |
Month 7
|
|
Risk taking between groups
Délai: Baseline
|
Balloon Analogue Risk Task (BART) |
Baseline
|
|
Risk taking between groups
Délai: Month 4
|
Balloon Analogue Risk Task (BART) |
Month 4
|
|
Risk taking between groups
Délai: Month 7
|
Balloon Analogue Risk Task (BART) |
Month 7
|
|
Decision making under risk conditions between groups
Délai: Baseline
|
Game Dice Task (GDT) |
Baseline
|
|
Decision making under risk conditions between groups
Délai: Month 4
|
Game Dice Task (GDT) |
Month 4
|
|
Decision making under risk conditions between groups
Délai: Month 7
|
Game Dice Task (GDT) |
Month 7
|
Collaborateurs et enquêteurs
Les enquêteurs
- Chercheur principal: Clémentine Estric, CHU de Nimes
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- NIMAO/2022-1/CE-01
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
All IPD that underlie results in a publication
Délai de partage IPD
Upon publication
Critères d'accès au partage IPD
The IPD will be made available to other researchers upon reasonable request to the corresponding author
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
- CIF
- ANALYTIC_CODE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .